Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Meclizine dihydrochloride
Cat. No.:
OB0225LY-0165
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
Meclizine dihydrochloride is an antihistamine used primarily to relieve dizziness and nausea caused by motion sickness.
Synonym:
Meclozine dihydrochloride; NSC28728; Meclizine 2HCl; 1104-22-9; 1-((4-Chlorophenyl)(phenyl)methyl)-4-(3-methylbenzyl)piperazine dihydrochloride; Ancolan dihydrochloride; 1-[(4-Chlorophenyl)(phenyl)methyl]-4-[(3-methylphenyl)methyl]piperazine dihydrochloride; Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]-, dihydrochloride; Parachloramine dihydrochloride
CAS No.:
1104-22-9
Compound CID:
64713
Formula:
C25H27ClN2·2HCl
Formula Weight:
463.87
Specification
Relative Density:
1.159 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Meclizine dihydrochloride can be used to study the mechanisms of vertigo.
Library Information
Targets:
Histamine receptor
Receptors:
H1 receptor
Pathways:
Neuronal signaling; Apoptosis; Immunology/Inflammation; GPCR/G protein
Plate Number:
AOCL-3
Plate Location:
a8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
15 mg/mL; 32.34 mM
